No intervention was applied in this study.: No intervention was applied in this study.
Study summary
The primary aim of the study was to determine the validity and reliability of the "MAP-Hand (Measure of Activity Performance of the Hand)" scale in patients with carpal tunnel syndrome. The secondary aim of the study was to evaluate the hand activity performance in patients with carpal tunnel syndrome.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
1. Age 18 and above and able to read and write
2. Diagnosed with mild or moderate unilateral CTS according to electroneuromyography results at least 6 months ago
3. Motor-sensory symptoms such as numbness and loss of strength in the hand for at least three months
4. Volunteers with no history of diabetes, no medical treatment or injections, no surgery, and no cervical radiculopathy or polyneuropathy
Exclusion Criteria:
1. Those with trauma, deformity, fracture, muscle contracture and atrophy in the shoulder, forearm and hand
2. Those who have received corticosteroid injections into the carpal tunnel area within the last three months and have been included in a physiotherapy program
3. Those who have cognitive problems
Primary outcome measure(s)
Hand Activity Performance — 24 weeks The MAP-Hand (Measure of Activity Performance of the Hand) scale is a scale consisting of 18 items that evaluates the activity performance of the hand. These items are scored between 1 and 4 and the total score ranges from 18 to 72. Lower scores indicate better activity performance. The participants' hand activity performance will be evaluated with the MAP-Hand scale. The reliability and validity of the Turkish form of the MAP-Hand scale was conducted by Bayraktar and colleagues. However, their work has not yet been published. The necessary permissions have been obtained to use the scale.
Trial sites (1)
Facility
City
Region
Status
Kirsehir Ahi Evran University
Kırşehir
Merkez
More Kirsehir Ahi Evran Universitesi trials in Turkey
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.